CU6.AX

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd

A$2.11

+0.02 +0.96% today

Price History

Not enough data

Key Stats

Market Cap

787.20M

Avg Volume

2.20M

EPS

-A$0.29

52W High

A$5.87

52W Low

A$1.80

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-7.92

P/B Ratio

4.23

P/S Ratio

74.78

EV/EBITDA

-5.56

EV/Revenue

57.12

Margins

Gross Margin 100.0%

Operating Margin (1095.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(1.1%)

Return on Equity

(77.5%)

Return on Assets

(45.1%)

Liquidity & Leverage

Current Ratio

16.09

Quick Ratio

15.49

Total Cash

178.25M

Total Debt

About

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.